Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
Jefferies Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $598
Buy Rating on Biogen: Anticipating Positive Reversal and Global Market Strength for Lecanemab
Icon Analyst Ratings
A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $497 to $598
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $350 to $380
Argenx Analyst Ratings
Vertex Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Truist Adjusts Price Target on ICON to $383 From $367, Maintains Buy Rating
Argenx Se (ARGX) Gets a Hold From UBS
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (ALGN) and Gilead Sciences (GILD)
Hold Rating on Gilead Sciences Amidst Q2 Revenue Shortfall and Competitive Pressures
Buy Rating Affirmed: Argenx Se's Financial Success and Clinical Promise
JMP Securities Sticks to Their Buy Rating for Argenx Se (ARGX)
TD Cowen Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $373
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating
Wells Fargo Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $547